Factors Associated with Prognosis of Non-Alcoholic Fatty Liver Disease

Main Article Content

Muamar M. A. Shaheen
Mohanad Saleh
Deema Sider
Reem Al Natsheh
Raghad Dweik

Abstract

Background: At the junction between obesity, metabolic syndrome and liver failure, lies Non-alcoholic fatty liver disease. Recent studies elaborated on role of metformin in patients with non-alcoholic fatty liver disease. This observation has not been studied at a global scale, neither it was investigated in different ethnical groups.

Objectives: We aim at determining the risk factors associated with prognosis of non-alcoholic fatty liver disease among a cohort of patients in Southern West Bank, Palestine.

Methods: A retrospective cohort study involving 300 NAFLD patients who visited the internal medicine department at Hebron Governmental Hospital from October 2017 till September 2018. Two hundred and three patients diagnosed with non-alcoholic fatty liver disease, were included in this study. Lab test results within the past 6 months, comorbidity and medication history were collected from patients` profiles. Data was analyzed using SPSS V20. Liver Fibrosis score was determined by using non-alcoholic fatty liver disease fibrosis score calculator.

Results: Two hundred and three non-alcoholic fatty liver disease patients (58.6% females), 54.78 (±12.27) years old were included in the study. Almost 65.5% of these patients have BMI >30 Kg/m2. It was found that, 62.25% of the 58 diabetic patients in this study had liver fibrosis score > 0.676 comparing to non-alcoholic fatty liver disease patients who are non-diabetic. There was a significant relationship between diabetes and fibrosis score, α=0.000. There was also a significant relationship between hyperlipidemia and fibrosis score of non-alcoholic fatty liver disease patients, α=0.023. We found a significant relationship between fibrosis score and hypertension, α=0.000. In the same context, there was a significant relationship between NAFLD patients who were on statin therapy and those who were not using statin therapy, α= 0.015. Metformin was not associated with significant relationship between users and non-users non-alcoholic fatty liver disease subjects.

Conclusion: Diabetes mellitus, hypertension, hyperlipidemia and statin use were associated with  NAFLD prognosis.

Keywords:
Liver fibrosis score, hypertension, dyslipidemia, diabetes mellitus, metformin, non-alcoholic fatty liver disease

Article Details

How to Cite
Shaheen, M. M. A., Saleh, M., Sider, D., Natsheh, R. A., & Dweik, R. (2021). Factors Associated with Prognosis of Non-Alcoholic Fatty Liver Disease. Asian Journal of Research in Medical and Pharmaceutical Sciences, 10(2), 1-12. https://doi.org/10.9734/ajrimps/2021/v10i230158
Section
Original Research Article

References

Giorda C, Forlani G, Manti R, Mazzella N, De Cosmo S, Rossi MC, et al. AMD-annals study group. Occurrence over time and regression of nonalcoholic fatty liver disease in type 2 diabetes, Diabetes/Metabolism Research And Reviews. 2017;33.4:e2878.‏

Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases, Hepatology. 2018;67(1):328-357.‏

Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the US, Hepatology. 2014;59(6):2188-2195.

Stättermayer AF, Traussnigg S, Aigner E, Kienbacher C, Huber-Schönauer U, Steindl-Munda P, Stadlmayr A, et al. Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome, Journal of Trace Elements in Medicine and Biology. 2017;39:100-107.‏

Buzzetti E, Pinzani M, EA Tsochatzis. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD), Metabolism. 2016;65(8):1038-1048.‏

Nuñez‐Durán E, Aghajan M, Amrutkar M, Sütt S, Cansby E, Booten SL, et al. Serine/threonine protein kinase 25 antisense oligonucleotide treatment reverses glucose intolerance, insulin resistance, and nonalcoholic fatty liver disease in mice, Hepatology communications. 2018;2(1):69-83.‏

Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease, Digestive diseases. 2010;28(1):155-161.‏

ZM Younossi, AB Koenig, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta‐analytic assessment of prevalence, incidence, and outcomes, Hepatology. 2016;64(1):73-84.‏

Chiloiro M, Caruso MG, Cisternino AM, Inguaggiato R, Reddavide R, Bonfiglio CV. Ultrasound evaluation and correlates of fatty liver disease: A population study in a Mediterranean area, Metabolic syndrome and related disorders. 2013;11(5):349-358.‏

Zelber‐Sagi S, Nitzan‐Kaluski D, Halpern Z, Oren R. Prevalence of primary non‐alcoholic fatty liver disease in a population‐based study and its association with biochemical and anthropometric measures, Liver International. 2006;26(7): 856-863.‏

Benedict M. Zhang X. Non-alcoholic fatty liver disease: An expanded review. World Journal of Hepatology. 2017;9(16):715.‏

Sookoian S, Pirola CJ. Systematic review with meta‐analysis: Risk factors for non‐alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients, Alimentary pharmacology and therapeutics. 2017;46(2):85-95.‏

Asrih M, FR Jornayvaz. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link? Molecular and Cellular Endocrinology. 2015;418:55-65.‏

Jung U, NS Choi. Obesity and its metabolic complications: The role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease, International journal of molecular sciences. 2014;15(4):6184-6223.‏

Bugianesi E, Moscatiello S, MF Ciaravella, Marchesini G. Insulin resistance in nonalcoholic fatty liver disease, Current pharmaceutical design. 2010;16(17):1941-1951.‏

BC Shil, Saha M, Ahmed F, SC Dhar. Nonalcoholic fatty liver disease: study of demographic and predictive factors, Euroasian Journal of Hepato-Gastroenterology. 2015;5(1):4.‏

Masarone M, Federico A, Abenavoli L, Loguercio C, Persico M. Nonalcoholic fatty liver: Epidemiology and Natural History, Reviews On Recent Clinical Trials. 2014;9(3):126-133.‏

Hamaguchi M, Kojima T, Ohbora A, Takeda N, Fukui M, Kato T. Aging is a risk factor of nonalcoholic fatty liver disease in premenopausal women, World journal of Gastroenterology: WJG. 2012;18(3):237.‏

Hamaguchi M, Kojima T, Takeda N, Nakagawa TH. Taniguchi Fujii K, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease, Annals Of Internal Medicine. 2005;143(10):722-728.‏

Amarapurkar D, Kamani P, Patel NP. Gupte Kumar P, Agal S, et al. Prevalence of non-alcoholic fatty liver disease: Population-Based Study, Annals of Hepatology. 2007;6(3):161-163.‏

Marino L, Jornayvaz FR. Endocrine causes of nonalcoholic fatty liver disease, World Journal of Gastroenterology: WJG. 2015; 21(39):11053.‏

Suzuki A, Abdelmalek MF. Nonalcoholic fatty liver disease in women, Women’s health. 2009;5(2):191-203.‏

Brady CW. Liver disease in menopause, World Journal of Gastroenterology. 2015; 21(25):7613.‏

Marino L, Jornayvaz FR. Endocrine causes of nonalcoholic fatty liver disease, World Journal of Gastroenterology: WJG. 2015; 21(39):11053.‏

Luyckx FH, Lefebvre PJ, Scheen AJ. Non-alcoholic steatohepatitis: Association with obesity and insulin resistance, and influence of weight loss, Diabetes and Metabolism. 2000;26(2):98-106.‏

Yoshitaka H, Hamaguchi M, Kojima T, Fukuda T, Ohbora A, Fukui M. Nonoverweight nonalcoholic fatty liver disease and incident cardiovascular disease: A Post Hoc Analysis of a Cohort Study, Medicine. 2017:96(18).

Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD), Metabolism. 2016;65(8):1038-1048.‏

Jornayvaz FR, Shulman GI. Diacylglycerol activation of protein kinase Cε and hepatic insulin resistance, Cell metabolism. 2012; 15(5):574-584.‏

Clark JM, Brancati FL, Diehl AM. Nonalcoholic Fatty Liver Disease, Gastroenterology. 2002;122:1649-57.

Miyake T, Kumagi T, Hirooka M, Furukawa S, Koizumi M, Tokumoto Y, et al. Body mass index is the most useful predictive factor for the onset of nonalcoholic fatty liver disease: a community-based retrospective longitudinal cohort study, Journal of Gastroenterology. 2013;48(3): 413-422.‏

Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis, World Journal of Gastroenterology. 2018;24(30):3361.‏

JA Bell, Kivimaki M, Batty GD, Hamer M. Metabolically healthy obesity: what is the role of sedentary behaviour? Preventive Medicine. 2014;62:35-37.‏

Owen N, Sparling PB, Healy GN, Dunstan DW, Matthews CE. Sedentary behavior: emerging evidence for a new health risk, Mayo Clinic Proceedings. 2010;85:1138-1141.

Hallsworth K, Thoma C, Moore S, Ploetz T, Anstee QM, Taylor R, et al. Non-alcoholic fatty liver disease is associated with higher levels of objectively measured sedentary behaviour and lower levels of physical activity than matched healthy controls, Frontline Gastroen- terology. 2015;6:44-51. Levine JA. Sick of sitting, Diabetologia. 2015;58:1751-1758.‏

Wei H, Qu H, Wang H, Deng H. Associations between sitting time and non-alcoholic fatty liver diseases in Chinese male workers: A cross-sectional study, Biomedical Central Journal-Open. 2016:6.

Ryu S, Chang Y, Jung HS, Yun KE, Kwon MJ, Choi Y, et al. Relationship of sitting time and physical activity with non-alcoholic fatty liver disease, Journal Of Hepatology. 2015;63:1229-1237.

Trenell MI. Sedentary behaviour, physical activity, and NAFLD: Curse of the chair, Journal of Hepatology. 2015;63(5): 1064-1065.‏

Gerber L, Otgonsuren M, Mishra A, Escheik C, Birerdinc A, Stepanova M, et al. Non‐alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population‐based study, Alimentary Pharmacology and Therapeutics. 2012;36(8):772-781.‏

Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis, Hepatology. 2012;56(3):943-951.‏

Kawaguchi T, Taniguchi E, Itou M, Sakata M, Sumie S, Sata M. Insulin resistance and chronic liver disease, World Journal Of Hepatology. 2011;3(5):99.

AL Birkenfeld, GI Shulma. Nonalcoholic fatty liver disease, hepatic insulin resistance and type 2 diabetes, Hepatology. 2014;59(2):713-723.

Williams KH, Shackel NA, Gorrell MD, McLennan SV, Twigg SM. Diabetes and nonalcoholic fatty liver disease: A Pathogenic Duo, Endocrine Reviews. 2012;34(1):84-129.

Bhatt HB, Smith RJ. Fatty liver disease in diabetes mellitus, Hepatobiliary Surgery and Nutrition. 2015;4(2):101.

Lallukka S. Non-alcoholic fatty liver disease: The role of insulin resistance, inflammation and the PNPLA3 I148M variant, Dissertationes Scholae Doctoralis Ad Sanitatem Investigandam Universitatis Helsinkiensis, 2018.

Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: Sites and mechanisms, Diabetologia. 2005;48 (4):634-642.

Mills EP, Brown KPD, Smith JD, Vang PW, Trotta K. Treating nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A review of efficacy and safety, Therapeutic Advances In Endocrinology And Metabolism. 2018;9(1):15-28.

Cholankeril R, Patel V, Perumpail B, Yoo E, Iqbal U, Sallam S. et al. Anti-diabetic medications for the pharmacologic management of NAFLD, Diseases. 2018; 6(4):93.

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes, 2015: A patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes, Diabetologia. 2015;58(3):429-442.

Prat LI, Tsochatzi EA. The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD), Hormones. 2018;1-11.

Rakoski MO, Singal AG, Rogers MAM, Conjeevaram H. Meta‐analysis: Insulin sensitizers for the treatment of non‐alcoholic steatohepatitis, Alimentary pharmacology and therapeutics. 2010; 32(10):1211-1221.

Tacelli M, Celsa C, Magro B, Giannetti A, Pennisi G, Spatola F, et al. Antidiabetic drugs in NAFLD: The accomplishment of two goals at once? Pharmaceuticals. 2018; 11(4):121.

Paul SK, Shaw JE, Montvida O, Klein K. Weight gain in insulin‐treated patients by body mass index category at treatment initiation: New evidence from real‐world data in patients with type 2 diabetes, Diabetes, Obesity and Metabolism. 2016; 18(12):1244-1252.

Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Anti-diabetic medications and the risk of hepatocellular cancer: A systematic review and meta-analysis, The American Journal Of Gastroenterology, 2013;108(6):881.

Ryysy L, Häkkinen AM, Goto T, Vehkavaara S, Westerbacka J, Halavaara J. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients, Diabetes. 2000;49(5):749-758.‏

Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms, Nature Reviews Cancer. 2004;4(8):579-591.

Inkster B, Zammitt NN, Frier BM. Drug-induced hypoglycaemia in type 2 diabetes, Expert Opinion On Drug Safety. 2012;11(4):597-614.

Goh GBB, Pagadala MR, Dasarathy J. Diabetes mellitus, insulin, sulfonylurea and advanced fibrosis in non-alcoholic fatty liver disease, Journal Of Diabetes And Metabolism. 2014;5:1-5.

Hazlehurst JM, Woods C, Marjot T, Cobbold JF, Tomlinson JW. Non-alcoholic fatty liver disease and diabetes, Metabolism. 2016;65(8):1096-1108.

Oikonomou D, Georgiopoulos G, Katsi V, Kourek C, Tsioufis C, Alexopoulou A, et al. Non-alcoholic fatty liver disease and hypertension: coprevalent or correlated? European Journal of Gastroenterology & Hepatology. 2018;30(9):979-985.

Aneni EC, Oni ET, Martin SS, Blaha MJ, Agatston AS, Feldman T, et al. Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk, Journal Of Hypertension. 2015;33(6):1207-1214.

Shim KY, Eom YW, Kim MY, Kang SH, Baik SK. Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension, The Korean Journal of Internal Medicine. 2018;33(3):453.

Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steato hepatitis, New England Journal of Medicine. 2017;377(21):2063-2072.

Nseir W, Shalata A, Marmor A, Assy N. Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease, Digestive Diseases And Sciences. 2011;56(12):3439-3449.‏

Sahebkar A, Sahebkar GT, Watts GF. New peroxisome proliferator-activated receptor agonists: Potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease, Expert Opinion On Pharmacotherapy. 2014;15(4):493-503.

Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: An update, Metabolism. 2016;65(8):1109-1123.‏

Carr RM, Ahima RS. Pathophysiology of lipid droplet proteins in liver diseases, Experimental cell research. 2016;340(2): 187-192.‏

Ress C, Kaser S. Mechanisms of intrahepatic triglyceride accumulation, World Journal of Gastroenterology. 2016; 22(4):1664.‏

Alkhouri N, Eng K, Lopez R, Nobili V. Non-high-density lipoprotein cholesterol (non-HDL-C) levels in children with nonalcoholic fatty liver disease (NAFLD), Springerplus. 2014;3(1):407.‏

Chatrath H, Hemant R, Chalasani N. "Dyslipidemia in patients with nonalcoholic fatty liver disease, Seminars In Liver Disease. 2012;32(1).

Athyros VG. GREACE study collaborative group: Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: A Post-Hoc Analysis, Lancet. 2010;376:1916-1922.‏

Sigler MA, Congdon L, Edwards KL. An evidence-based review of statin uses in patients with nonalcoholic fatty liver diseas, Clinical Medicine Insights: Gastroenterology. 2018;11:1179552218787502.‏

Zhang QQ, Lu LG. Nonalcoholic fatty liver disease: Dyslipidemia, risk for cardiovascular complications, and treatment strateg, Journal of Clinical and Translational Hepatology, 2015;3(1):78.‏

Hyogo H, Tazuma S, Arihiro K, Iwamoto K, Nabeshima Y, Inoue M, et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia, Metabolism. 2008;57(12): 1711-1718.‏

Magan-Fernandez A, Rizzo M, Montalto G, Marchesini G. Statins in liver disease: Not only prevention of cardiovascular events, Expert Rev. Gastroenterol. Hepatol. 2018;12:743-744.‏

Zhang J, Wang L, Wu B, Gao N, Kang N. Effect of atorvastatin combined with metformin on the lipid metabolism, hyperinsulinemia and oxidative stress in patients with nonalcoholic fatty liver disease, Journal of Hainan Medical University. 2017;23(9):60-63.‏

Imprialos KP, Stavropoulos K, Doumas M, Skalkou A, Zografou I, Athyros VG. The potential role of statins in treating liver diseas, Expert Review of Gastroenterology & Hepatology. 2018;12(4):331-339.